Subscribe
10 November 2017Americas

LSIPR 50 2017: Brian Singerman

Name: Brian Singerman

Organisation: Founders Fund

Position: Partner

Brian Singerman is a partner of Founders Fund, a venture capitalist firm which achieved a return of $1.7 billion after it sold California-based biotechnology company Stemcentrx to AbbVie in 2016.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk




Editor's picks

Americas
Bernie Sanders blasts big pharma for ‘ripping off’ patients
8 February 2024

Editor's picks

Americas
Bernie Sanders blasts big pharma for ‘ripping off’ patients
8 February 2024
Americas
Pfizer and BioNTech allege inconsistencies in Moderna’s COVID-19 statements
1 February 2024
Biotechnology
Force pharma companies to provide drugs for rare cancer trials, UK govt told
30 January 2024
Biotechnology
USPTO hands win to Daiichi Sankyo in cancer drug dispute
18 January 2024
Americas
SCOTUS urged to remedy ‘threat’ to patent law in sleep drug feud
16 January 2024
Big Pharma
SCOTUS rejects big pharma’s challenge to USPTO power
9 January 2024

More features

US agency warns 10 pharma companies of filing ‘bogus’ patents
BioNTech’s patent juggling act: protecting innovation amid IP challenges
USPTO veteran joins Finnegan as of counsel in Washington, DC
CureVac and Acuitas wind up COVID-19 vaccine dispute
Amgen and Sandoz settle dispute over blockbuster bone condition drugs
GSK: Pfizer, BioNTech ‘reaped billions of dollars’ from stealing COVID-19 patents
GSK settles HIV drug licensing dispute
Meeting the cell and gene therapy scale-up challenge